Navigation Links
Important Drug Product Notice: Luitpold Pharmaceuticals, Inc. Announces Temporary Suspension of Distribution and Manufacture of Drug Products
Date:4/21/2011

SHIRLEY, N.Y., April 21, 2011 /PRNewswire/ -- Luitpold Pharmaceuticals, Inc. ("Luitpold") today announced that it has temporarily suspended distribution of all of its drug products manufactured at its Shirley, New York facility and marketed by its American Regent, Inc. subsidiary and Animal Health Division.  This action DOES NOT affect products manufactured at its PharmaForce Inc. subsidiary, including its Betamethasone Sodium Phosphate and Betamethasone Sodium Acetate Injectable Suspension, USP. Osteohealth and Regency Therapeutics Division products, including SPRIX® (Ketorolac Tromethamine) Nasal Spray are not affected.

As a result of a recent inspection and a follow-up meeting with FDA on April 14, 2011, Luitpold agreed to temporarily suspend distribution of any drug product manufactured at its Shirley, New York facility.  (It had previously suspended the manufacture of its drug products on its own initiative).

Luitpold is in the process of developing a plan, in conjunction with outside consultants and the FDA, that will allow it to resume manufacturing and distribution of its drug products as soon as possible.  Luitpold Pharmaceuticals, Inc. will provide further information on its estimated timetable to resume supply of products to the market in the near future.

Luitpold has communicated with the FDA Drug Shortage Staff regarding this issue, and will work with them to address potential shortages of drug products critical to patient health.  

Any questions concerning this notice should be directed to the American Regent Customer Service Department at 1-800-645-1706 or the Animal Health Division at 1-800-458-0163.


'/>"/>
SOURCE Luitpold Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Important Drug Information Notice Regarding Sodium Thiosulfate Injection, USP, 10% (100mg/mL), 10mL Single Dose Vials and 25% (250mg/mL), 50mL Single Dose Vials
2. Important Drug Information Notice Regarding Potassium Phosphates Injection, USP, 3 mM/mL Phosphorous; 4. 4 mEq/mL Potassium: 5 mL, 15 mL and 50 mL Single Dose Vials
3. PNP Therapeutics Meets Important Financial and Regulatory Objectives in Development of New Cancer Therapies
4. Urgent: OTC DRUG Nationwide Recall--Important information for patients about IV PREP Antiseptic Wipes
5. ICAP Ocean Tomo Announces Four Patent Sets From Oxford Instruments - Each Represents an Important Advancement in Technology
6. Avantra Biosciences and MedTrust Online Partner to Develop Clinically Important Protein Biomarker Assays for Improving Cancer Care
7. Ardea Biosciences Earns $15 Million Payment from Bayer HealthCare AG for Achievement of Important Clinical Milestone in Ongoing Collaboration
8. Important Information for Betaseron® (interferon beta 1-b) Consumers Regarding Triad Groups Alcohol Prep Products
9. AVMA Offers Important Guidance to DEA on New Controls for Induction Agent—Propofol
10. Activity Against Key Drug-Resistant Pathogens is the Most Important Attribute Influencing Surveyed Physicians Antibiotic Selection for Nosocomial Pneumonia in the U.S.
11. Cardium Announces New Research Findings: Excellagen Product Candidate Activates Platelet Release of PDGF, an Important Growth Factor Fundamental to the Wound Healing Process
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... Calif. , June 23, 2016 Any dentist ... many challenges of the current process. Many of them do ... of the technical difficulties and high laboratory costs involved. And ... to offer it at such a high cost that the ... it. Dr. Parsa Zadeh , founder of ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
Breaking Medicine Technology:
(Date:6/27/2016)... California (PRWEB) , ... June ... ... pioneer in the patient payment industry today announced its strategic partnership with ... health system workflows. , The two companies’ proven, proprietary technology combine to ...
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating ... Millions of individuals in the United States and Canada wear eyeglasses. Once considered to ... correct vision and make a fashion statement. Even celebrities use glasses as a way ...
(Date:6/26/2016)... ... 2016 , ... On June 10-11, 2016, A Forever Recovery, a holistic treatment ... Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is located. This ... of the world’s leading providers of cereal and other breakfast foods. Its residents often ...
(Date:6/26/2016)... , ... June 26, 2016 , ... PawPaws brand ... new product that was developed to enhance the health of felines. The formula is ... The two main herbs in the PawPaws Cat Kidney Support Supplement Soft ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women ... diagnosed with endometriosis. These women need a treatment plan to not only alleviate ... that can help for preservation of fertility and ultimately achieving a pregnancy. The ...
Breaking Medicine News(10 mins):